FDA Approves Lilly’s Jaypirca for First-Line CLL/SLL Treatment

The regulatory decision follows data from the Phase 3 BRUIN CLL-313 clinical trial, which demonstrated that pirtobrutinib significantly delayed disease progression compared to standard chemoimmunotherapy. In the study, patients treated with the inhibitor showed an overall response rate of 94%, with a hazard ratio of 0.20 for progression-free survival. These findings were previously presented at the American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology.

Dr. Jennifer A. Woyach, a hematologist-oncologist at The Ohio State University Comprehensive Cancer Center, noted that the approval allows clinicians to introduce targeted therapy earlier in the care continuum. As many patients today receive only one or two lines of treatment, the efficacy and tolerability of initial choices remain critical. Jaypirca, which is also recommended by the National Comprehensive Cancer Network, operates through a novel binding mechanism that targets the BTK pathway, distinguishing it from conventional covalent inhibitors. While the drug offers a new therapeutic route, prescribing information includes warnings regarding potential side effects, such as infections, hemorrhage, and cardiac arrhythmias.